Standard BioTools initiated with a Buy at Jefferies

Jefferies initiated coverage of Standard BioTools with a Buy rating and $3.25 price target. The analyst says the company’s refreshed focus on building a platform of differentiated tech for scale and profitability is underappreciated. The firm scopes for a multiple to re-rate as management executes and visibility around the mid-term profit picture becomes more tangible.